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1. Introduction 
Heterotrimeric guanine nucleotide-binding proteins 
(G proteins) form a growing family of proteins medi- 
ating signal transduction from the outside of the cell 
to the cytoplasm by interacting with receptor and 
effector proteins (for review see Refs. [1-8]). G 
proteins are composed of three subunits, et, [3 and % 
of which at least 23 (including splice variants) differ- 
ent et forms (Get), 6 different [3 forms (G[3) and 11 
different ~ forms (G~) exist. The family of G-pro- 
tein-coupled receptors consists of at least 1000 differ- 
ent polypeptides of which several hundreds have 
been cloned and sequenced. Their common features 
are external amino (N) terminus, cytoplasmic carboxy 
(C) terminus and seven stretches of hydrophobic 
amino acids which are thought o span seven times 
the cytoplasmic membrane, thereby generating three 
extra- and three intracellular loops. Binding of the 
ligand to the extracellular binding pocket of the 
receptor is assumed to induce a conformational change 
which causes exchange of GDP for GTP on the 
coupled G-protein et subunit, dissociation of Get[3~ 
from receptor and release of the G[3~/dimer f om the 
Get-GTP. Both the activated GTP-bound et subunit 
and free [3 ~/ subunits have the capability of activating 
or inactivating different effector systems, e.g. adeny- 
lyl cyclases, phospholipases C-[3 and ion channels, 
whereby Get and G[3~ act independently from each 
other, in some cases as antagonists or as synergists. 
The intrinsic GTPase activity of the Get terminates 
the activation of the et subunit, which then in its 
GDP-bound form reassociates with the G[3"~/dimer. 
A given receptor interacts with a limited set of G 
proteins to affect a given effector system. A few 
years ago, it was assumed that the specificity in 
receptor-G protein-effector coupling is only deter- 
mined by the et subunit of the G protein, but today a 
large body of evidences upports the idea that in 
addition to the et subunits the [3~/ dimers determine 
G-protein specificity. This increases the number of 
hypothetical receptor-G protein-effector combinations 
from several hundreds to thousands. Our review will 
focus to the question how the antisense technology 
can be used to determine the identity of individual 
subtypes of G-protein subunits involved in signal 
transduction cascades. 
2. Specificity of receptor-G protein and G pro- 
tein-effector interactions 
In order to determine which G protein mediates 
signal transduction from a given receptor to its effec- 
tor system various approaches have been used in 
membrane preparations as well as in intact cells. A 
method used with membrane preparations i the la- 
belling of receptor-activated G proteins with the 
non-hydrolysable azidoanilido-[et- 32p]GTP analog 
(AA-GTP) [9]. After agonist-induced activation of G 
proteins and GDP/GTP exchange, the GTP analog 
becomes chemically crosslinked to the activated et 
subunits (Get). The identity of the Get is determined 
by using specific antibodies for immunoprecipitating 
of the analog-labelled et subunits [10]. Results of this 
method point to the type of G protein to which a 
particular activated receptor is able to couple, but 
allows only limited conclusions whether this coupling 
is of relevance for interaction with an effector sys- 
tem. In addition, the affinity of some G-protein et 
subunits for the GTP analog is different [11]. This 
makes interpretations of time-courses and concentra- 
tion response curves for the GTP analog difficult at 
least in some instances. 
Peptide antibodies pecifically recognizing the C- 
termini of different et subunits have been used to 
prevent he interaction of the G proteins with recep- 
tors in membrane preparations or intact cells after 
microinjection of the antibodies. This method was 
used to demonstrate he coupling of TSH receptor via 
G s to adenylyl cyclase [12], to prevent he coupling 
of muscarinc receptors to K + channels by Gq, to 
prevent he coupling of adrenergic et2 receptors to 
vo l tage-gated  Ca  2+ channels [13,14], and to elucidate 
the function of Gi2 in serum-stimulated DNA synthe- 
sis [15]. 
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Purified G proteins, receptors and effectors as well 
as those expressed recombinantly in bacterial cells or 
in Sf9 insect cells were used to reconstitute signal 
transduction cascades in artificial membrane systems 
and, thereby, to detect possible specificities in inter- 
action. This approach was used, e.g., to demonstrate 
stimulation of cGMP phosphodiesterase by G t ( for  
review see Ref. [16]), stimulation by G s and inhibi- 
tion by G i of adenylyl cyclases (for review see Ref. 
[17]), and stimulation of phospholipases C-[3 by the 
members of the Gq-farnily as well as by G[3~ (for 
review see Refs. [18] and [19]). Purified and recombi- 
nant G proteins were used also for reconstitution 
experiments in intact cells. In these experiments he 
activity of endogenous G proteins was diminished by 
pretreating the cells with pertussis toxin. In this way, 
stimulation of K ÷ channels by [3~/ dimers [20], inhi- 
bition of Ca 2+ channels by G O in neuronal cells [21], 
or stimulation of Ca 2+ channels by G s in cardiac 
cells could be demonstrated [22]. In these studies the 
purified or recombinant G proteins were infused into 
the cells via the patch pipette. Another group recon- 
stituted the inhibition of voltage-gated Ca 2÷ channels 
by microinjection of pnrified G O proteins into cells 
[23]. 
Cotransfection of plasmids carrying cDNAs of G- 
protein subunits together with cDNA plasmids for 
effectors or receptors into cells not expressing the 
repsective ndogenous G proteins is another method 
to investigate signal transduction pathways. 
There are two major disadvantages of all the ap- 
proaches ummarized above to investigate receptor-G 
protein-effector coupling as a whole or in parts. First, 
the membrane homing, location and vicinity of recep- 
tors, G proteins and effectors is likely to be different 
from the natural situation. Second, the balance of 
local concentration and numbers of molecules of all 
components in a particular signal transduction event 
is artificial and not controlled in reconstitution and 
overexpression studies. 
3. Antisense DNA/RNA approaches 
In recent years the antisense DNA/RNA technol- 
ogy has attracted much attention. It enables re- 
searchers to inhibit selectively the biosynthesis of one 
particular molecular species and to investigate which 
cell function is lost (for reviews see Refs. [24-28]). 
In principal, several ways exist to inhibit the expres- 
Table 1 
G-protein functions detected by expression of antisense RNA a 
Receptors G protein Effector system Cells References 
somatostatin o'. o VOC $ GH4C 1 [32] 
somatostatin o'. i2 AC ,~ GH4C 1 [32] 
somatostatin o,. i2 AC $ FTO-2B [38] 
A 1 adenosine o'.i2 AC $ FTO-2B [38] 
M 4 muscarinic o'. o VOC $ GH4C I [32] 
M 4 muscarinic o'. i2 AC $ GHnC i [32] 
D2c, D2s dopamine o, i2 AC $ GHnC I [32] 
D2L, D2s dopamine 0% VOC ,1, GH4C I [32] 
TRH e'..~ AC $ GH 3 [35] 
VIP e, .~ AC $ GH 3 [35] 
fMLP o: o [ Ca2 + ]i $ HL-60 [33] 
LTB 4 o% [ Ca2+ ]i $ HL-60 [33] 
LTB4 °t i2 AC $ HL-60 [33] 
o', i2 differentiation F9 [36] 
CLi2 AC, body weight, liver mass, fat mass transgenic mice [38] 
C~. i2 PTP 1B transgenic mice [40] 
a Abbreviations used: AC, adenylyl cyclase; [Ca2+] i, cytosolic calcium concentration; fMLP, formyl-Met-Leu-Phe; LTB4, leukotriene 
B4; PTP1B, phosphotyrosine phosphatase type 1B; TRH, thyrotropin-releasing hormone; VIP, vasoactive intestinal polypeptide; VOC, 
voltage-operated calcium channels; $, inhibition; T, stimulation. 
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sion of one gene selectively. One is the transcription 
of that mRNA in antisense orientation within the 
cells. For this purpose the target sequence is recom- 
bined in reversed orientation with an expression plas- 
mid and the construct ransfected or injected into the 
cells of interest. The length of the transcribed anti- 
sense RNA can vary from 40-50 to several hundred 
nucleotides. Antisense sequences can also be deliv- 
ered as synthetic oligoribo- or oligodeoxyribonu- 
cleotides. Various chemical modifications may be 
introduced to increase the stability or the cellular 
uptake of the oligomers as far as modifications do not 
impair with recognition of the complementary se- 
quence (for review see Refs. [27] and [29]). Different 
methods were used to inhibit the expression of G 
proteins (for recent reviews see Refs. [30] and [31]). 
4. Inhibition of G-protein subunit biosynthesis by 
transcription of antisense RNA 
4.1. Transcription of long antisense RNA directed 
against G proteins 
Stable expression of antisense RNA can be used 
for nearly complete depletion of cells from the mRNA 
encoding a particular G-protein subunit. Table 1 gives 
an overview on such studies. Following transfection 
of antisense RNA expression constructs together with 
a resistance marker gene, cells have to be clonally 
selected for high level antisense RNA transcription. 
Liu et al. [32] used subclones of the pituitary cell line 
GHaC l stably expressing the long and the short 
forms of the dopamine D 2 receptor. These cells were 
then transfected for a second time with constructs for 
transcription of eL o and o~i2 antisense RNA. The 
plasmids were constructed by inserting a 2.1-kilobase 
e~ol or a 1.8-kilobase o/.i2 cDNA fragment in reverse 
orientation with respect to a cytomegalovirus pro- 
moter. The cDNA fragments comprised the entire 
coding sequences of either subunit. In addition, 5'-un- 
translated sequences were included for the e~o anti- 
sense construct and 3'-untranslated sequences in the 
case of the c~i2 antisense construct, to increase the 
specificity in annealing to the complementary mRNA. 
The resulting e~ o antisense construct blocked the 
expression of both the c~ ol and c~ 02 subunits, whereas 
the oLi2 antisense construct specifically blocked the 
expression of the o~i2 subunits. For selection of trans- 
fected cells, a plasmid carrying a hygromycin-resis- 
tance gene was cotransfected with the antisense RNA 
transcription constructs. In clones with highest tran- 
scription of antisense constructs, eL o mRNA was 
completely eliminated and e~i2 mRNA was reduced 
in concentration. These subclones were functionally 
characterized with respect o inhibition of Ca 2+ in- 
flux induced by the dihydropyridine Ca 2+ channel 
opener Bay K 8644. The cytoplasmic alcium con- 
centration was determined by fura-2; inhibition of 
adenylyl cyclase by activation of transfected D2L and 
D2s receptors as well as by activation of the endoge- 
nous M 4 and somatostatin receptors was measured as 
a second effector system. In different subclones, the 
inhibition of calcium influx induced by activated D2s, 
M 4 and SST receptors was completely abolished by 
expression of the oL o antisense RNA construct. Inhi- 
bition by the D2L receptor was only reduced by 70%, 
even in subclones in which no mRNA coding for e~ o 
or 0~i2 protein could be detected. Inhibition of basal 
cAMP accumulation by these four receptors was 
completely abolished in all subclones in which the 
oLi2 antisense RNA was transcribed. The authors also 
investigated the inhibition of vasoactive intestinal 
peptide (VIP)-stimulated cAMP accumulation in the 
e~i2 antisense RNA transcribing clones. The inhibi- 
tion by activated D2L and M 4 receptors was com- 
pletely abolished, whereas the inhibition by activated 
D2s receptors was reduced by only 30%. Paradoxi- 
cally, the VIP-stimulated cAMP accumulation was 
increased by activation of SST receptors in these 
cells depleted of Ge~i2 mRNA. The same group also 
showed this adenylyl cyclase activation in a clone 
transcribing the Get i2 antisense RNA and stably ex- 
pressing 5-HT1A receptors [31]. The authors ex- 
plained these curious results by a potentiation of 
Gs-activation of adenylyl cyclase by an excess of [3~/ 
subunits released from Gi] or G O in the Gai2-de- 
pleted cells. Nevertheless, they demonstrated a clear 
difference in coupling of the closely related D2s and 
D2L receptors to voltage-gated Ca 2+ channels as well 
as to adenylyl cyclases. 
In cells constitutively transcribing antisense RNA 
one has to take care that subcloning procedures do 
not alter the expression of other components in a 
particular signal transduction cascade. This could 
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change the specificity and degree of coupling be- 
tween the components under investigation. To over- 
come these problems, Goetzl et al. [33] used transient 
transcription of Geeil, Gee i2, Gee i3 and Gee ol anti- 
sense RNA from constructs transfected into HL-60 
cells by lipofection. The antisense constructs were 
identical to those used by Liu et al. [32]. Maximal 
repression (80-95%) of target proteins as analyzed 
by Western-blotting was reached 6-7 days after 
transfection. It was reported that suppression of Gee o 
but not of Gee i protein expression partially reduced 
the responses to the chemotractants fMLP and LTB 4 
in these cells as measured by diminished increases in 
intracellular Ca 2+, [3-glucuronidase release and 
chemotaxis. Inhibition of adenylyl cyclase was af- 
fected in cells transfected with the Gee i2 antisense 
RNA-transcribing construct. These results are surpris- 
ing in functional aspects because Gee o is a G protein 
mostly expressed in neuronal and neuro-endocrine 
tissue. Expression of this. protein in leukemic cells as 
in HL-60 has never been described. In addition, 
coupling of G O to phospholipase C has not been 
shown for mammalian systems. However, Chen et al. 
[34] demonstrated coupling of the 5-HT2c receptor to 
PLC via G O in Xenopus oocytes by using injection of 
antisense oligonucleotides specific for Gee o and the 
subtypes of Geei. 
Paulssen et al. [35] used a similar approach to 
target the expression of Get s in the rat pituitary cell 
line GH 3. A part of the coding sequence of Gees 
cDNA was recombined followed by the known part 
of the 3'-noncoding sequence in reverse orientation 
with a plasmid driving transcription by the inducible 
metallothionine promoter. The plasmid was trans- 
fected by electroporation i to GH 3 cells; 24 h after 
induction of the promoter with CdC12, a concentra- 
tion-dependent reduction of Gee s mRNA and protein 
of up to 95% was measured. The VIP-induced in- 
crease in cAMP was reduced by up to 30% in 
transfected cells, and the TRH-induced increase in 
cAMP was reduced by up to 85%. The Gpp(NH)p-in- 
duced increase in cAMP was unaffected by transcrip- 
tion of the Got s antisense RNA. These results indi- 
cate that even after 95% reduction of Gee~ protein 
and mRNA the remaining Gee~ molecules are suffi- 
cient to mediate a couplSing to the effector system in 
these cells. One can speculate also that different 
receptors need different amounts of G proteins to 
accomplish full functional coupling to an effector 
system. 
4.2. Transcription of short antisense RNA directed 
against G proteins 
The studies described so far demonstrate that the 
transcription of antisense RNA effectively suppresses 
protein expression. One limitation of this methods 
arises from the length of the antisense RNA. If 
antisense RNAs of several hundred nucleotides are 
used, the selective knockout of one member in gene 
families, like in those for [3 and "y subunits of G 
proteins, cannot be achieved. The untranslated re- 
gions which in most of the known genes contain a 
sufficiently high sequence variability are not known 
for most of the [3 and ~/ subunit genes of G proteins 
and can, therefore, not be utilized for long antisense 
transcripts. 
The best solution for this problems are the anti- 
sense RNAs used by Watkins et al. [36]. This group 
constructed very short antisense constructs which 
transcribe only 39 bases of the 5'-untranslated region 
including the ATG translation start codon. Sequences 
for Geelp Geei2, Geei3 and Gee o were cloned in 
reverse orientation into a retroviral expression vector. 
These constructs were used to create recombinant 
viruses for efficient infection of cell lines and subse- 
quent stable integration of the vector into the cellular 
genome. Subclones with constitutive high levels of 
transcription of short antisense RNA can easily be 
selected. The specificity and the advantages of these 
constructs for short antisense RNA transcription were 
shown for Gee iz. A clone transcribing the 39 nu- 
cleotides long Gee i2 antisense RNA at high level 
reduced the cellular content of Geei2 protein by up to 
85%. When in F9 stem cells Gee i2 expression was 
knocked out by antisense transcription from this con- 
struct, the ability of thrombin to inhibit forskolin- 
stimulated adenylyl cyclase was decreased by 70%. 
In addition, these cells changed their morphology 
following retinoic acid-induced ifferentiation, dis- 
playing an endoderm-like morphology. The authors 
confirmed the results by stable transfection of F9 
cells with an expressing construct for a constitutively 
active mutant of Gee 12. The transfected cells did not 
differentiate when retinoic acid was applied. These 
findings revealed an important role for Gee i2 in dif- 
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ferentiation. The same Ga i2 antisense construct was 
used by this group to show that in F9 teratocarcinoma 
cells and in rat osteosarcoma 17/2.8 cells, where 
GoL ~2 was depleted, the basal accumulation of inositol 
phosphates was increased. Stimulation of phospholi- 
pase C by different hormones was potentiated [37]. 
A similar strategy was used to target the G~i2 
mRNA in transgenic mice. A segment of 39 base 
pairs from the 5'-untranslated region just in front of 
the translation start was recombined in antisense ori- 
entation embedded within the cDNA for the phospho- 
enolpyruvate carboxykinase (PEPCK) gene. The 
PEPCK promoter is active only in fat cells, liver and 
kidney at birth [38,39]. The major characteristics of 
transgenic mice transcribing the short antisense RNA 
in these tissues was their failure to thrive. This was 
remarkably seen in reduction of body weight and 
blunted skeletal growth. In adipocytes isolated from 
transgenic animals as well as in rat hepatoma cells 
transfected with the same antisense construct, the 
basal cAMP accumulation was increased and the 
hormonal-induced inhibition of adenylyl cyclase was 
reduced. These findings confirmed the important role 
for Ga  ~2 as transducer for the inhibition of adenylyl 
cyclase [39]. In a subsequent paper the authors howed 
that the mice deficient of Ga  i2 displayed a phenotype 
of insulin resistance characteristic of non-insulin-de- 
pendent diabetes mellitus, e.g. runted phenotype, fast- 
ing hypoinsulinaemia, nd impaired glucose and in- 
sulin tolerance [40]. In adipocytes derived from trans- 
genic animals insulin mediated phosphorylation of 
insulin receptor substrate-1 (IRS-1) is reduced com- 
pared to adipocytes from control animals, which could 
be explained by increased phosphotyrosine phos- 
phatase (PTPase) activity caused by high expression 
rate of the enzyme subtype PTP1B and release of this 
enzyme from its membrane associated endoplasmic 
reticular localization to the cytosol. This could be 
found in adipocytes, liver cells and skeletal muscle 
cells of antisense RNA expressing animals. These 
results suggest Gi2 as a link between insulin receptors 
and phosphotyrosine phosphatase lB. A phenotype 
Table 2 
G-protein functions detected by injection of antisense oligonucleotides a 
Receptors G protein Effector system Cells Refs. 
somatostatin c¢ oJ [31~/3 VOC $ GH 3, RINm5F [57],[58] 
M 4 muscarinic O/.o1133'~4 VOC $ GH 3 [59] 
M2/4 muscarinic c%t[33'~4 VOC $ PC-12 Kalkbrenner t al., unpubl. 
galanin O/- o1133'~/4 VOC $ GH 3, RINm5F [59] 
galanin c~ o1132~  VOC ,], GH 3, RINm5F [59] 
GABA B c~ o VOC $ DRG [60] 
D 2 dopamine c~ o VOC $ lactotropes [53] 
5-HT2c et o, ~ i l PLC 1" Xenopus oocytes [34] 
TRH a i2/i3 VOC $ GH 3 [66] 
D 2 dopamine ai3 K ÷ channel 1" lactotropes [50] 
galanin eL i3 AC $ RINm5F [46] 
8-opioid ot_i2 [ Ca2+ ]i 1' ND8-47 [47] 
I~-opioid c~ i2 antinociception mice (intraventricular) [73] 
a s differentiation 3T3-L 1 [45] 
TRH a q/1 I VOC ]" GH 3 [63] 
M muscarinic oLll K + channel $ VMH [46] 
M i muscarinic c¢ q/a 11 [31/[34"/4 [ Ca2 + ]i $ RBL-hm 1 [67] 
A 3 adenosine c~ i3 [32"/2 [ Ca2 + ]i ~' RBL-hm 1 Dippel et al. unpubl. 
~x I adrenergic OLq/O/~11131/[33"¥2/'¥3 [Ca2+]i $ portal vein myocytes [69] 
neuromedin B a q PLC $ Xenopus oocytes [76] 
M 3 muscarinic a q / i i PLC $ Xenopus oocytes [75] 
a Abbreviations used: AC, adenylyl cyclase; [Ca2+]i, cytosolic calcium concentration; DRG, dorsal root ganglion neurones; PLC, 
phospholipase C; TRH, thyrotropin-releasing hormone; VMH, ventromedial hypothalamic neurones; VOC, voltage-operated calcium 
channels; $, inhibition; q', stimulation. 
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similar to that described for Got i2-deficient transgenic 
mice has been described in mice with disrupted IRS-1 
gene [41,42] 
The approach to use inducible and tissue specific 
transcription of short antisense RNA in transgenic 
animals has advantages and disadvantages compared 
to knock-outs created by homologous recombination 
[43]. Most noticeable is the advantage that lethal 
effects in utero can be avoided since antisense tran- 
scription starts at birth. In addition, transcription 
restricted to certain tissues opens the opportunity to 
investigate the effects of gene suppression i  tissues 
and interesting subsels. Compared to genomic 
knock-outs, it is impossible to achieve a complete 
absence of the target mRNA; by now the extent o 
which the targeted protein has to be reduced to get 
the intended loss of function is not clear. The first 
described genomic knock-out of a G protein was the 
disruption of Got i2 by homologous recombination 
[44]. Transgenic mice with a loss of Got i2 function 
were runted, developed ulcerative colitis, and occa- 
sional adenocarcinoma of the colon aside from the 
retardation of growth. Prior to clinical symptoms, the 
mice showed alteration in thymocyte maturation and 
function with similarities to transgenic mice express- 
ing the S1 subunit of pertussis toxin. However, from 
this study it is not cleaJ whether the immunological 
defect is a prerequisite :for the defects in gut epithe- 
lium. 
5. Inhibition of G-protein subunits biosynthesis by 
using antisense oligodeoxynucleotides 
Antisense oligonucleotides are often delivered to 
cells as short oligodeoxyribonucleotides, i. . 15-35 
residues long. Fifteen base pairs is the minimum 
length to target antisense oligonucleotides specifi- 
cally to only one kind of transcript of the entire 
mRNA. This length range facilitates the search for a 
unique target sequence of a particular mRNA out of 
the mRNAs coding for a highly related gene family 
like that for [3 subunits of G proteins. Since the 
hybridization temperature is fixed to 37°C, oligo- 
nucleotides longer than 25-30 nucleotides will not 
necessarily increase specific annealing of the oligo- 
nucleotide to the targeted RNA. Table 2 summarises 
the studies in which antisense oligonucleotides di- 
rected against G proteins were used so far. 
5.1. Application of antisense oligodeoxynucleotides 
by addition to cell culture medium 
One method for application of antisense oligo- 
nucleotides to cells is addition of oligonucleotides at 
high concentrations to the cell culture medium. The 
oligonucleotides will be taken up by passive diffusion 
or by active transport mechanisms. An active trans- 
port was demonstrated in HL-60 cells [45], and simi- 
lar mechanisms are postulated for other cells. 
In cultured ventromedial hypothalamic neurons 
from rat, carbachol-induced suppression of the out- 
ward delayed rectifying potassium current was re- 
duced after treating the cells with antisense phos- 
phorothioate oligonucleotides, designed to anneal to 
ot-subunit mRNA of Gll [46,47]. The oligonucleo- 
tides were used at a concentration f 10 ~M, and the 
time period of treatment was 24-48 h. Other anti- 
sense oligonucleotides complementary to sequences 
of Got q or sense oligonucleotides resembling se- 
quences of Got ll were without effect on potassium 
current. 
Wang et al. [48] applied antisense oligonucleotides 
annealing to the mRNA of Got s, Gotil and Goti3 into 
the medium of 3T3-L1 fibroblasts at 30 ixM. Dexam- 
ethasone/methylisobutylxanthine induced ifferentia- 
tion of these fibroblasts into adipocytes occurred after 
3 days in cells treated with Got s antisense oligo- 
nucleotide compared to 7-10 days in control cells. In 
addition, treatment of fibroblasts with Got s antisense 
oligonucleotides by itself induced differentiation of 
the cells within 7 days. Other sense and missense 
oligonucleotides used in this study had no conse- 
quence on differentiation. After incubation of cells 
with the Got s antisense oligonucleotides for 48 h the 
expression of the respective proteins was reduced by 
more than 90% as indicated by Western-blotting. The 
results of this work raise some interesting questions 
about the role of G s proteins in such complex biolog- 
ical processes as cellular differentiation. 
de Mazancourt et al. [49] determined the ot subunit 
of G i proteins mediating alanin-induced inhibition 
of adenylyl cyclase in RINm5F cells by applying 
subtype specific phosphorothioate antisense oligo- 
nucleotides repeatedly for 12 h to cells in serum-free 
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medium at concentrations from 1 to 10 ixM. By 
applying oligonucleotides at 5 IxM, the protein ex- 
pression of various a subunits was specifically de- 
creased by 41-47% as shown by Western blots with 
specific antibodies. Treating cells with Gc~i3 anti- 
sense oligonucleotides totally blocked the galanin-in- 
duced inhibition of forskolin-stimulated a enylyl cy- 
clase activity in RINm5F cells. This means that 
reduction in protein expression by half resulted in an 
apparent loss of protein function. The authors ex- 
plained this by the fact that a large amount of the G i 
proteins is associated with Golgi membranes and 
only a limited population of Gi3 proteins is localized 
at the plasma membrane and is there available for 
galanin receptors. Analyses of fractionated mem- 
branes of RINm5F cells by Western-blotting indeed 
showed a significant amount of G~3 protein associated 
with microsomal membranes [49]. 
Tang et al. [50] used antisense oligonucleotides 
directed against G proteins to elucidate which G 
protein mediates the increase in [Ca2+] i induced by 
g-opioid receptors in neuroblastoma × dorsal root 
ganglion hybrid cells (ND8-47). They treated the 
cells for up to six days with partially protected 
phosphorothioate oligonucleotides at the concentra- 
tion of 10 txM. The cell culture medium contained 
0.5% serum and was replenished together with fresh 
oligonucleotides very 48 h. The amount of the re- 
spective G proteins declined after four days of treat- 
ment of ND8-47 cells and was significantly reduced 
after six days of oligonucteotide treatment, as shown 
by Western-blotting experiments. Unfortunately, the 
authors did not give exact data on quantification of 
protein contents. The opioid-induced increase in 
[Ca2+]i was reduced in cells treated with antisense 
oligonucleotides directed against GoLi2. In time 
courses the reduction of the functional effect paral- 
leled the decrease in the respective protein amount in 
these cells. Thus, from these experiments and from 
experiments with inhibitors of voltage-gated calcium 
channels the authors concluded that the g-opioid 
receptor in ND8-47 cells stimulates voltage-gated 
calcium channels via GoLi2 and in this way raises 
[Ca2+ ]i. 
Application of antisense oligonucleotides to the 
medium can be an attractive way to administer oligo- 
nucleotides to cells because very high numbers of 
cells can be treated with oligonucleotides. This al- 
lows for quantification of effector systems not mea- 
surable in single cell assays, e.g. of adenylyl cyclase, 
phospholipases C, D and A 2 or of more complex 
processes, e.g. differentiation, growth, secretion and 
chemotaxis. On the other hand, high concentration f
oligonucleotides in the medium are required to over- 
come degradation and to obtain reasonable ffects. 
This may cause nonspecific effects although success- 
ful examples for G-protein-mediated effects have been 
published as summarised above. We performed simi- 
lar experiments and used up to 100 IxM of either 
unprotected or protected oligonucleotides and did not 
obtain reproducible ffects with G-protein antisense 
oligonucleotides neither on effector systems nor on 
RNA expression as measured by reverse transcriptase 
(RT)-PCR experiments. The addition of cationic lipo- 
somes [51] did not improve our results in three cell 
lines studied, i.e. GH 3, RINm5F and RBL-2H3. We 
quantified the uptake of 32 P-end-labeled oligonucleo- 
tides. At the optimal ratio of liposomes to oligo- 
nucleotides (1.4-2.7 to 1) we found that maximally 
15% of the antisense oligonucleotides were taken up 
by the cells, an amount which was obviously not high 
enough to induce any cellular effects (Dippel, Kalk- 
brenner and Schultz unpublished results). However, 
the failure of detection of significant oligonucleotides 
uptake in our experiments may depend on the cell 
lines used. Recently, Crooke et al. [52] showed that 
the pharmacokinetics of phosphorothioates antisense 
oligonucleotides in tissue culture can vary as a func- 
tion of cellular assay conditions and analytical meth- 
ods used (e.g. time, temperature, concentration, se- 
quence of the oligonucleotides, cell lines and meth- 
ods for labeling and detection of oligonucleotides). 
5.2. Application antisense oligodeoxynucleotides 
through the patch-clamp ipette 
Baertschi et al. [53] used a method to introduce 
antisense oligonucleotides into single cells. They 
patch-clamped BSA gradient-enriched cultured lac- 
totrophes from lactating rats twice. During the first 
patching period, the cells were dialyzed for 160 
seconds in average with antisense oligonucleotides 
which were able to anneal to the mRNA of Gcx o, 
GOLil, Goti2 , Goti3 and Gc~s; 48 h later, the same 
cells were patch-clamped a second time, and the 
dopamine-induced inhibition of voltage-gated cal- 
F. Kalkbrenner et al. / Biochimica et Biophysica Acta 1314 (1996) 125-139 133 
cium current and the increase in voltage-activated 
potassium current were measured. Inhibition of cal- 
cium current was reduced by dialyzing the cells with 
anti-s o antisense oligonucleotides, whereas the in- 
crease in potassium current was abolished by dialyz- 
ing the cells with anti-e~3 antisense oligonucleotides. 
The authors reported that by substituting four guanine 
with four cytosine bases within the core of the anti-a ol 
antisense oligonucleotide the specificity of the oligo- 
nucleotide inhibiting GoL o expression when compared 
to Gall,  Goti2 and Goti3 is increased [53]. The 
efficacy of these changes was demonstrated in an in 
vitro translation assay. The greatest advantage of the 
dialyzing method compared to microinjection of anti- 
sense oligonucleotides is that the cells can be chosen 
by functional parameters before oligonucleotides will 
be applied. However, patch-clamping is much more 
damaging to cells than microinjection. In addition, 
oligonucleotides applied, to the cytoplasm will be 
exposed to degradation by unspecific endo- and ex- 
onucleases, which reduces the amount of antisense 
oligonucleotides available for annealing to their tar- 
get mRNA in the nucleus. 
5.3. Nuclear microinjection of antisense 
oligodeoxynucleotides irected against G O proteins 
Kleuss et al. [54] e,;tablished the repression of 
biosynthesis of G-protein subunits by microinjection 
of antisense oligonucleotides into the nuclei of single 
cells (for experimental details see Ref. [55]). Fig. 1 
shows the general strategy used. First, cells were 
grown on marked cover slips, then antisense 
oligodeoxynucleotides, generally 20-30 nucleotides 
long and designed to anneal specifically to the mR- 
NAs of subtypes of ~, [3 and 7 subunits of G 
proteins, were injected into the nuclei of single cells. 
To measure microinjection efficiency, cells were in- 
jected with fluorescein i,;othiocyanate (FITC)-marked 
oligonucleotides; the fluorescence signal was de- 
tected in the nuclei of about 90% of the injected cells. 
After 2 to 4 days the G protein function was deter- 
mined by measuring hormonally induced inhibition 
of voltage-gated Ca 2+ channels. To determine which 
type of G proteins couples a given hormone receptor 
to voltage-gated Ca 2+ channels in GH 3 cells, Kleuss 
et al. [51] microinjectecl antisense oligonucleotides 
into the nuclei of these cells; the oligonucleotides 
cultur ing of cells on glass slides 
1 
injection of ATGGATGATCG--sense DNA 
oligonucleotides A U G G A U G i U C 0 - -  tuRN A 
into nuclei of cells z ,~  ~zv D ±v~ ~- -ant i sense  
1 
incubation of cells 
1 
measuring calcium 
current in whole 
cell configuration 
or 
measuring 
calcium release 
in single cells 
oligonucleotide 
. . . . . . . . . .  
L 
Fig. h General strategy for determination of functional G-protein 
heterotrimers by microinjection of antisense oligonucleotides into 
the nucleus of single cells. 
were designed to hybridize to the mRNA of Gaol 
and Go~o2 subunits. To check whether the oligo- 
nucleotides are able to suppress biosynthesis of the 
respective proteins, the G-protein a subunits were 
visualized by using an affinity-purified o~ common anti- 
body recognizing the a s, oL i, (x o, a z and o~ t subunits 
of G proteins, and the cells were monitored by im- 
munofluorescense microscopy. Antisense oligo- 
nucleotides complementary to the o~-subunit mRNAs 
of all pertussis toxin-sensitive G proteins and G z 
(a-com) suppressed the corresponding proteins one 
day after injection of oligonucleotides. GoL-proteins 
expression re-occurred on the third day after injec- 
tion. The function of the G o protein, measured as 
inhibition of voltage-gated Ca 2+ channels, was re- 
duced in a similar time-dependent manner. The largest 
reduction was seen 48 h following injection of anti- 
sense oligonucleotides. After 72 h channel function 
had completely recovered. By nuclear injection of 
antisense oligonucleotides selectively targeted for the 
mRNA coding for the Ga o subtypes GOLol and GO~o2, 
the authors were able to demonstrate hat the somato- 
statin receptor couples to GO~o2 and that the mus- 
carinic M 4 receptor couples to GOtol to inhibit the 
voltage-gated Ca 2+ channel in these cells. 
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This study was extended to the [3 and ~/ subunits 
of G proteins. In two subsequent papers Kleuss et al. 
[56,57] demonstrated, also by using the nuclear injec- 
tion of antisense oligonucleotides that the G proteins 
coupling the somatostatin receptors to the voltage- 
gated Ca 2+ channels are composed of the subunits 
OLo2131~/3 and that the G proteins coupling the mus- 
carinic M 4 receptor to the same effector system are 
composed of the subunits oL ol [33"/4. The specificity in 
coupling of a given receptor to a certain het- 
erotrimeric G protein is identical in other cell models. 
In PC-12 cells the muscarinic M2/4 receptor uses the 
same trimer as in GH 3 cells to inhibit the voltage- 
gated Ca 2+ channels; the same is true in RINm5F 
cells for the somatostatin receptor (Ref. [58] and see 
Fig. 4). 
Studying the identity of the G protein coupling the 
galanin receptors to voltage-gated Ca 2+ channels, 
Kalkbrenner et al. [59] demonstrated that one receptor 
couples via two different G-protein heterotrimers to
the same effector system. From the quantity of anti- 
sense effects on function and from coexpression data 
of [3"y dimers, they deduced that galanin receptors in 
GH 3 and RINm5F cells couple preferentially to G- 
protein trimers consisting of O/.o1132"~2 and less effi- 
ciently to trimers consisting of ao~[33~4, hetero- 
trimers which are also used by the M 4 muscarinic 
receptor (Ref. [57] and see Fig. 4). 
Campbell et al. [60] used the technique of micro- 
injection of antisense oligonucleotides to analyze 
which G protein couples the GABA B receptor to 
voltage-operated Ca 2+ channels in root dorsal gan- 
glion cells. In cells injected with an anti-a o antisense 
oligonucleotide common for either splice variant of 
GoL o the baclofen-induced inhibition of voltage-oper- 
ated Ca 2+ channels was reduced to 21% compared to 
34-38% in control, nonsense or anti-oL i oligonucleo- 
tide-injected cells. Staining of Ge~ o with GOtocommo n 
antibodies was reduced by 76% in cells injected with 
anti-oL o antisense oligonucleotides whereas staining 
of GoLi with GoLicommon antibodies was not reduced. 
However, injection of anti-oL i antisense oligonucleo- 
tides, designed to anneal to the mRNAs of all oL~ 
subunits, reduced the staining of Ga i by 68% but did 
not influence Ga o staining. These data suggest hat 
the level of G proteins in these cells has to be 
reduced by two thirds before observing measurable 
functional effects by injected antisense oligonucleo- 
tides. In studies in RINm5F cells concerning the 
coupling of G o to voltage-gated Ca 2+ channels, the 
reduction in immunofluorescence paralleled the re- 
duction in G-protein function, i.e. 50% reduction in 
protein level of Ga ol resulted in 50% reduced inhibi- 
tion of voltage-gated Ca 2+ channels [59]. 
5.4. Determination of the specificity of antisense 
effects 
Kalkbrenner et al. [59] showed subtype-specific 
reduction in protein expression of GCXol and GO~o2 
when RINm5F cells were injected with anti-O~o~ and 
anti-C~o2 antisense oligonucleotides, respectively. In 
these experiments, 48 h after injection the immuno- 
fluorescence signal of GOtol was reduced in cells 
injected with O~ol antisense oligonucleotides com- 
pared to cells injected with 0%2 antisense oligo- 
nucleotides and vice versa; in cells injected with OLo2 
antisense oligonucleotides the immunofluorescence 
signal of GOLo2 was reduced compared to cells in- 
jected with a ol antisense oligonucleotides. 
Another important proof of specificity of the anti- 
sense effects comes from the selectivity of loss in 
function. In one and the same cell, in which antisense 
oligonucleotides annealing to the [31 subunit were 
injected, the inhibition of voltage-gated Ca 2+ chan- 
nels by somatostatin was diminished, but the inhibi- 
tion induced by carbachol and galanin was still pre- 
sent. Vice versa the inhibition of Ca 2+ channels by 
galanin was diminished in cells injected with [32 
antisense oligonucleotides, but the inhibition induced 
by somatostatin a d carbachol was still present in one 
and the same cell. For composition of heterotrimers 
coupling M 4 muscarinic, somatostatin and galanin 
receptors to voltage-gated Ca 2+ channels ee Fig. 4. 
Similar results were obtained by injecting antisense 
oligonucleotides annealing to the mRNAs of G-pro- 
tein 13 and ~/ subunits [61]. 
Thus, the most convincing demonstration for the 
high degree of selectivity by which one particular 
trimer of subunits is used for receptor-effector cou- 
pling comes from the subsequent application of sev- 
eral hormones. Activation of at least two different 
receptors by their cognate hormones and measure- 
ments conducted on one and the same cell would 
obviously reveal nonspecific effects of the injected 
antisense oligonucleotides. It is well known that 
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oligodeoxynucleotides containing phosphorothioate 
modifications in their backbone bind in a more or 
less unspecific manner to proteins (e.g. see Refs. [62] 
and [63]). This may explain the effects of p53, c-myb 
and c-myc antisense oligonucleotides [64,65] on cell 
proliferation which were recently identified as not 
being related to antisense-mediated g ne suppression 
but rather to effects caused by certain sequences, i.e. 
clusters of three or four guanosine in the case of the 
c-myb and the c-myc antisense oligonucleotides [65]. 
In microinjection studies performed in our laboratory, 
non-specific effects were observed at concentrations 
of oligonucleotides higher than 70 IxM (concentration 
of injection solution) completely protected by phos- 
phorothioate linkages. 
Therefore, we strongly recommend that antisense 
experiments should generally include the comparison 
of two related pathways in one and the same cell, 
allowing for internal controls similar to those de- 
scribed above. 
5.5. Nuclear microinjection of antisense 
oligodeoxynucleotides irected against Gq and G i 
proteins 
By injecting antisense oligonucleotides which tar- 
geted mRNA sequences of Ga q, Gal l ,  Ga z and 
Gai2 and Gai3, Gollasch et al. [66] showed that two 
pathways are involved in TRH-induced stimulation of 
voltage-gated Ca 2+ channels in GH 3 cells. On one 
hand, Gai2 is required for stimulation of Ca 2+ cur- 
rents. On the other hand, Gq/ll-mediated stimulation 
of phospholipase C with subsequent activation of 
protein kinase C is necessary for phosphorylation f a 
signal transduction component (e.g. a Ca 2+ channel 
or G-protein subunit), which finally results in stimu- 
lation of voltage-gated Ca 2+ channels. 
Recently Dippel et al. [67] extended the antisense 
studies to another effector system, namely phospholi- 
pase C-[3 (PLC-[3). They determined the increase in 
the intracellular Ca 2+ concentration [Ca2+]i in cal- 
cium-free solution by fura-2 in single cells. Fig. 2A 
shows the results of a typical experiment in which rat 
basophilic leukemia cells stably expressing the hu- 
man muscarinic ml receptor (RBL-2H3-hml; Ref. 
[68]) were injected with antisense oligonucleotides 
annealing to the mRNAs of aq, a l l  and ct]4 sub- 
units of G proteins. The cells injected with the aq 
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Fig. 2. Carbachol-induced increase in [Ca 2+ ]~ in RBL-2H3-hml 
cells injected with antisense oligonucleotides irected against the 
mRNAs of GO, q, Ot. ll , ~14 and '~1. The increase in [Ca 2+ ]i is 
shown as a average of 15-40 cells in representative experiments. 
Cells were superfused with carbachol (1mM) at about 48 h after 
intranuclear injection with the indicated antisense oligonucleo- 
tides. Shown are two independent experiments in which oligo- 
nucleotides directed against Gc% (anti-c~q) and Gc~ll (anti-c~ 1 i)
were compared tooligonucleotides irected against Gc~ 14 (anti- 
al4) (A) or G~/I (anti-~l) (B). It should be noted that Ga14 but 
not G~/1 is expressed in this cell system. Numbers inparentheses 
indicate the number of cells measured for each oligonucleotide. 
and a u antisense oligonucleotides revealed a re- 
duced carbachol-induced increase in intracellular cal- 
cium compared to a14 antisense oligonucleotide- 
injected cells (Fig. 2A). Fig. 2B shows another exper- 
iments in which the cells injected with a q and al l  
antisense oligonucleotides revealed lower release of 
intracellular calcium induced by carbachol compared 
to cells injected with ~/1 antisense oligonucleotides. 
In summary, the results from RBL-2H3-hml cells 
indicate that ml receptors use specific G-protein 
complexes composed of aq, al l  , [~1' [~4 and "~4 to 
activate phospholipase C (Ref. [67] and see Fig. 4). 
In cells injected with anti-Ctq and anti-et 11 antisense 
oligonucleotides the amounts of the corresponding 
immunochemically detected proteins were reduced by 
85% after two days; the expression of Gaq and Ga 11 
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completely recovered after four days, demonstrating 
the reversibility of the antisense ffect (Fig. 3). PLC-[3 
in RBL cells is also activated by the endogenous 
adenosine A 3 receptor via a PTX-sensitive G protein, 
indicating that the PLC-[3 is activated by [3-¢ dimers 
released from receptor-activated G i proteins. Results 
with injection of antisense oligonucleotides annealing 
to the mRNAs of ot i, [3 and ~/ subunits of G proteins 
indicate that the adenosine A 3 receptor couples to the 
G-protein heterotrimer consisting of Go~i3132"y 2 to 
activate PLC-[3 in RBL-2H3 cells (Dippel, Kalkbren- 
A day 1 day 2 
ner, and Schultz unpublished). By using the same 
methods, e.g. nuclear microinjection of antisense 
oligonucleotides corresponding to the mRNA se- 
quences coding for G-protein a,  [3 and ~/subunits in 
combination with fluorometric determination of the 
increase in [Ca2+]i we showed that norepinephrine- 
induced Ca 2+ release from intracellular stores in 
primary rat portal vein myocytes is mediated by G 
proteins consisting of aq, O~lt, [31, [33, "~2 and ~/3 
[69]. 
Fig. 4 summarises the composition of functional 
heterotrimeric G proteins coupling receptors to effec- 
tors so far detected by using microinjection of anti- 
sense oligonucleotides. 
The question arises whether the specificity in het- 
erotrimers is due to a specific coupling of activated 
receptors to particular G-protein heterotrimers or to 
localization of G-protein heterotrimers and receptors 
in distinct areas of the plasma membrane, and thereby 
limiting the available combinations of receptors and 
G proteins. Indeed, there are indications that com- 
partmentalization may be an important principle in 
G-protein-mediated signal transduction (for review 
see Ref. [70]). In $49 lymphoma cells G-protein [3~/ 
subunits become sequestered in Triton-X-100 insolu- 
ble fractions together with cytoskeletal fragments 
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Fig. 3. Time course of the inhibition of GOtq/jl protein expres- 
sion in RBL-2H3-hml cells injected with anti-aq/=~ antisense 
oligonucleotides. (A) Immunofiuorescence of anti-c~ q ÷ i ~-injected 
cells. Cells were microinjected atthe day 0 with a mixture of a q 
and a~l antisense oligonucleotides and stained at the indicated 
time after injection with rabbit anti-aq/ll antiserum (AS 370) 
specific for G a q/ll (1:100), followed by staining with FITC-con- 
jugated goat anti-rabbit IgG (1:1000). (B) Quantification of im- 
munofluorescence data of injected cells. Images of the stained 
cells were obtained by a video imaging system using monochro- 
matic light of 495 nm at an exposure time of 1000 ms; to prevent 
bleaching, cells were not exposed before pictures were taken. The 
average of pixels outlined from the immunofluorescence of the 
cell membrane were corrected for background illumination and 
calculated for each cell by constant acquisition parameters. The 
digitalized fluorescence images were visualized by the software 
NIH Image (Wayne Rasband, NIH, Washington, USA). Shown 
are the percentage of arbitrary fluorescence units of the injected 
cells compared to non-injected control cells on the same cover 
slip which were always treated in the same way as injected cells 
(injected/control). The data for the indicated ays after injection 
of antisense oligonucleotides are shown. Error bars give standard 
deviation. 
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of Get q and Get ]~ antisense oligonucleotides each 
individually resulted in the same extend of inhibition 
of m3-receptor induced phospholipase C activity as 
did injection of  Get q/llcommon antisense oligonucleo- 
tides. PLC activity was determined as calcium-sensi- 
tive whole cell chloride current. However, in the 
same expression system, i.e. Xenopus laevis oocytes, 
the neuromedin B receptor selectively couples to 
Get q and not Get l~, as shown by injection of anti- 
sense oligonucleotides directed against Get q and Get i 1 
[76]. These results rise speculations that some PLC 
activating receptors may functionally distinguish be- 
tween Gq and G~ and other may not. 
Fig. 4. Summary of functionally interacting G-protein hetero- 
trimers for various receptors, as detected by intranuclear injection 
of antisense oligonucleotides directed against G-protein subunits 
in the cell lines indicated. 
[71]. In smooth muscle cells G-protein eL and [3 
subunits copurify with caveolin, an important struc- 
tural protein of plasmalemma c veolae [72]. Further- 
more, ~/5 subunits in neonatal cardiac fibroblasts 
colocalize in focal adhesions with vinculin [73]. In 
addition the mobility of rhodamin-labelled G-protein 
[3~/ subunits is limited, when reconstituted into lipid 
vesicles and added to intact NG108-15 cells by vesi- 
cle fusion [74]. Thus, compartmentalization of signal- 
ing components may prevent free movement of re- 
ceptors and G proteins in membranes, which may 
play an important role in the specific interactions 
between receptor and effectors. Taking into account 
all results, one may spe, culate that receptors interact 
locally with distinct pools of preformed specific G- 
protein heterotrimers presumably in caveolae of cell 
membranes. For Gq and G]I, available data indicate 
that preformed or precoupled complexes can include 
more than one heterotrimer. This model is supported 
by the fact that inhibition of the expression of only 
one of the involved subunits leads to abrogation of 
the functional coupling, which means that all subunits 
involved contribute equally to functional coupling 
[67]. Similar effects were described for suppression 
of m3 receptor-phospholipase C coupling by injection 
of antisense oligonucleotides directed against Getq 
and Get ll in Xenopus laevis oocytes [75]. Injection 
6. In vivo use of antisense oligodeoxynucleotides 
directed against G proteins 
Only one published study exists in which antisense 
oligonucleotides against G proteins were used in vivo 
in animal studies. Raffa et al. [77] intracerebroven- 
tricularly injected phosphorothioate antisense oligo- 
nucleotides directed against different G-protein et 
subunits to inhibit antinociception i duced by su- 
paraspinal ~t-opioid receptors. Injection of Geti2 anti- 
sense oligonucleotides but not the injection of Get il, 
Get i3 , and Get s antisense oligonucleotides into the 
ventricles of rats reduced the morphine-induced 
antinociception. Similar approaches were used to in- 
hibit functions of neuronal receptors in living brain 
(for review see Ref. [78]). 
7. Conclusions 
Targeting the individual G-protein subunits by an- 
tisense knock-out has led to the identification of 
specificity in receptor-G protein and G protein-effec- 
tor coupling in the genuine nvironment of the trans- 
membrane signal transduction system. Various meth- 
ods have been used, e.g. stable and transient expres- 
sion of antisense RNA in cells as well as in animals, 
and different ways of applications of antisense oligo- 
nucleotides with different modifications have been 
used. All these methods have their one restrictions, 
but all together provide useful tools to specifically 
target individual members in a highly related and 
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widely expressed family of proteins such as G pro- 
teins. It is this aspect hat makes G proteins accessi- 
ble as a possible target for future therapeutic ap- 
proaches as indicated by the study of Raffa et al. [77]. 
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